Skip to main content
Ernexa Therapeutics Inc. logo

Ernexa Therapeutics Inc. — Investor Relations & Filings

Ticker · ERNA ISIN · US6294106066 US Manufacturing
Open in API
Filings indexed 1,027 across all filing types
Latest filing 2025-04-03 Capital/Financing Update
Country US United States of America
Listing US ERNA

About Ernexa Therapeutics Inc.

https://www.ernexatx.com/

Ernexa Therapeutics Inc. is a biopharmaceutical company developing cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) and differentiates them into induced mesenchymal stem cells (iMSCs). These engineered iMSCs are designed as scalable, off-the-shelf treatments that leverage the natural ability of MSCs to home to sites of tumors or inflammation. Once at the target site, the cells deliver therapeutic payloads, such as cytokines, to modulate the immune system. The company's lead candidate, ERNA-101, is being developed for the treatment of ovarian cancer. Its pipeline also includes ERNA-201, a cell therapy designed to target inflammation in autoimmune diseases.

Recent filings

Filing Released Lang Actions
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes details about a securities purchase agreement, unregistered sales of equity securities, shareholder director nominations, and exhibits related to these agreements. There are no comprehensive financial statements or detailed financial performance data typical of annual or quarterly reports. The document primarily announces a material definitive agreement and related corporate actions, which aligns with updates on financing activities and capital structure changes. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8389 characters) and detailed description of the securities purchase agreement support this classification with high confidence.
2025-04-03 English
Board/Management Information 2025
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details an amendment to the company's articles of incorporation, including a name change and adoption of amended bylaws. There are no financial statements or detailed financial data presented, only corporate governance changes. This fits the category of Board/Management Information (MANG), which includes announcements of changes in the company's board or senior management or corporate governance structure changes such as amendments to articles or bylaws. The document length is under 5,000 characters and is a direct report, not an announcement of a report publication, so it is not RPA. It is not a full annual or quarterly report, nor an earnings release or other financial report. Therefore, the best classification is MANG with high confidence.
2025-03-26 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically the issuance of a promissory note, which is a financing activity. The document details the terms of the promissory note, interest rates, maturity, and default provisions. There is no comprehensive financial data or full financial statements, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or management report. The focus on a financing agreement and creation of a direct financial obligation aligns with Capital/Financing Update filings. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 6000 characters, which is sufficient for a substantive filing rather than a brief announcement. Confidence is high given the clear description of a financing event in a Form 8-K.
2025-03-24 English
Annual Report 2024
Annual Report FY 2024
2025-03-12 English
Capital/Financing Update 2025
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the issuance of a promissory note, a financing event where the company borrowed $1.5 million under specific terms. There are no financial statements or comprehensive financial data presented, only a description of the financing agreement and its terms. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is 5819 characters, sufficient to provide substantive detail about the financing event, not just a brief announcement. Therefore, the correct classification is CAP with high confidence.
2025-03-12 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-03-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.